Core Insights - Vor Bio has initiated the dosing of the first patient in the global Phase 3 UPSTREAM SjD trial for telitacicept, targeting adult patients with active primary Sjögren's disease [1][2] - Telitacicept is the only BAFF/APRIL inhibitor in Phase 3 development for Sjögren's disease, which currently lacks approved disease-modifying therapies [2][9] - The trial aims to enroll approximately 250 adult patients and will assess the efficacy and safety of telitacicept compared to placebo, with a primary endpoint focused on the EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) score at Week 48 [2][3] Company Overview - Vor Bio is advancing global development programs for autoimmune diseases, including ongoing trials for generalized myasthenia gravis (gMG) and Sjögren's disease to support potential regulatory approvals in the U.S., Europe, and Japan [7] - Telitacicept is already approved in China for systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and generalized myasthenia gravis (gMG), with additional regulatory filings for primary Sjögren's disease and IgA nephropathy underway [6] Disease Context - Sjögren's disease is a chronic autoimmune condition characterized by overactive B cells that damage moisture-producing glands, leading to symptoms such as dry eyes and mouth, fatigue, and systemic complications [3][4] - The disease is often underdiagnosed, with about half of the cases unrecognized, and predominantly affects women [4]

Core Insights - Vor Bio has initiated the first patient dosing in the Phase 3 UPSTREAM SjD trial for telitacicept, targeting primary Sjögren's disease, which currently lacks approved therapies [1][2] Company Overview - Vor Bio is a clinical-stage biotechnology company focused on transforming the treatment of autoimmune diseases [1] - The company is advancing global development programs for major autoimmune indications, including a Phase 3 trial for generalized myasthenia gravis (gMG) and primary Sjögren's disease (SjD) [7] Product Information - Telitacicept is a novel investigational recombinant fusion protein that inhibits BAFF and APRIL, two cytokines crucial for B cell survival, thereby reducing autoreactive B cells and autoantibody production [5] - Telitacicept is already approved in China for systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and generalized myasthenia gravis (gMG), with additional regulatory filings for SjD and IgA nephropathy (IgAN) underway [6] Clinical Trial Details - The UPSTREAM SjD trial will involve approximately 250 adult patients with active primary Sjögren's disease, evaluating the efficacy and safety of telitacicept compared to placebo [2] - The primary endpoint is the change in the EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) score at Week 48, with key secondary endpoints assessing systemic disease activity, glandular function, and patient-reported symptoms [2] Disease Context - Sjögren's disease is a chronic autoimmune condition characterized by overactive B cells leading to inflammation and damage to moisture-producing glands, with symptoms including dry eyes, dry mouth, fatigue, and systemic complications [3][4] - The disease is underdiagnosed, with about half of the cases unrecognized, and predominantly affects women [4]

Summary of Vor Biopharma Conference Call Company Overview - **Company**: Vor Biopharma - **Key Product**: Telitacicept, a BAFF/APRIL inhibitor targeting autoimmune diseases - **CEO**: Jean-Paul Kress Industry Context - **Focus**: Autoimmune diseases, specifically myasthenia gravis (gMG) and Sjögren's disease - **Market Potential**: gMG market projected to exceed $10 billion in the U.S. by the end of the decade [10] Core Insights and Arguments 1. **Telitacicept's Mechanism**: - Differentiated profile as a BAFF/APRIL inhibitor that remodulates the immune system without deep B-cell suppression [4][7] - Applicable to multiple autoimmune diseases, with clinical validation from RemeGen's late-stage trials [4][8] 2. **Clinical Development**: - Two global phase 3 trials initiated for gMG and Sjögren's disease, with the first patient in Sjögren's expected by mid-2023 [1][27] - gMG trial shows promising results with a placebo-adjusted improvement of -4.8, indicating strong efficacy [12] 3. **Safety Profile**: - Telitacicept has been administered to tens of thousands of patients in China, demonstrating a manageable safety profile with mostly mild to moderate adverse events [9][8] - No burdensome vaccination requirements or serious adverse events associated with B-cell depletion [9] 4. **Market Opportunity**: - gMG and Sjögren's disease represent multi-billion dollar opportunities, with Sjögren's being particularly difficult to quantify due to underdiagnosis [25][26] - Telitacicept aims to achieve blockbuster status in both indications, leveraging its unique treatment profile [5][26] 5. **Financial Position**: - Vor Biopharma has a strong balance sheet with $450 million, providing a runway until mid-2028 to support clinical trials and product development [6][27] Additional Important Points 1. **Long-term Treatment**: - Telitacicept allows for chronic treatment without the need for drug holidays, addressing a significant unmet need in autoimmune disease management [14][9] 2. **Clinical Trial Design**: - The global phase 3 trial for gMG is designed with 180 patients, with an extension period to assess long-term efficacy [15][16] - The Sjögren's trial will enroll 250 patients, randomized between active and placebo arms, with a focus on multiple endpoints [24][25] 3. **Competitive Landscape**: - Telitacicept is positioned against existing therapies, with a focus on its ability to provide a balanced approach without the drawbacks of B-cell depletion seen in other treatments [40][41] 4. **Regulatory Environment**: - The timing for the Sjögren's trial is favorable, as other companies are paving the way for approval in this indication [25] 5. **Future Outlook**: - Top-line data for the gMG trial is expected in the first half of 2027, with ongoing updates on progress [26][27] This summary encapsulates the key points discussed during the Vor Biopharma conference call, highlighting the company's strategic focus, product potential, and market opportunities in the autoimmune disease sector.

Core Insights - Vor Bio has appointed Dr. Jeremy Sokolove as Chief Medical Officer, bringing over 20 years of experience in rheumatology and autoimmune disease research [1][2] - Dr. Sokolove's previous roles include leadership positions at Roivant Sciences and Odyssey Therapeutics, focusing on clinical strategy and development of immunomodulators [2][3] - The company is advancing telitacicept, a dual-target fusion protein, through Phase 3 clinical development to address serious autoantibody-driven conditions [5] Company Overview - Vor Bio is a clinical-stage biotechnology company dedicated to transforming the treatment of autoimmune diseases [5] - The company aims to rapidly advance telitacicept towards potential commercialization, targeting patients with limited therapeutic options [5] Leadership and Expertise - Dr. Sokolove has extensive clinical experience as an internist and rheumatologist, with a strong publication record in immunology and rheumatology [3] - His academic credentials include board certification in internal medicine and rheumatology, and an MD from Boston University School of Medicine [3] Clinical Strategy - Dr. Sokolove expressed confidence in the BAFF/APRIL pathways to modulate mechanisms underlying autoimmune diseases, highlighting telitacicept as a promising therapeutic opportunity [4] - The company plans to execute a global clinical development program for telitacicept, aiming to improve patient outcomes [4]

Global Science. One Purpose. 48-week Phase 3 Clinical Trial Data from China for Telitacicept in Primary Sjögren's Disease October 28, 2025 Forward Looking Statement This presentation (the "Presentation") contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 about Vor Biopharma Inc. ("Vor," "Vor Bio" or the "Company"). The words "aim," "anticipate," "believe," "can," "could," "design," "enable" "estimate," "expect," "intend," "may," "ongoing," "plan," ...

Core Insights - Vor Bio announced significant results from a Phase 3 study of telitacicept for systemic lupus erythematosus (SLE), achieving a primary endpoint with 67.1% of patients responding compared to 32.7% with placebo [1][2] - The dual inhibition of BAFF and APRIL is validated as a transformative approach for B-cell targeting, indicating telitacicept's potential as a disease-modifying therapy for SLE [1][2] Company Overview - Vor Bio is a clinical-stage biotechnology company focused on transforming the treatment of autoimmune diseases, particularly through the development of telitacicept [8] - The company aims to advance telitacicept through Phase 3 clinical development and potential commercialization to address serious autoantibody-driven conditions globally [8] Study Details - The Phase 3 study was conducted at 42 hospitals in China, involving 335 patients with active SLE despite standard therapy [2] - The study met its primary endpoint with a statistically significant improvement in disease activity, as measured by the modified SLE Responder Index-4 (SRI-4) response at week 52 [1][2] Efficacy and Safety Findings - Telitacicept demonstrated improvements across multiple secondary measures, including a 70.1% reduction in SELENA-SLEDAI score compared to 40.5% for placebo [4] - The safety profile of telitacicept was consistent with previous studies, with serious adverse events occurring less frequently compared to placebo [3] Mechanism of Action - Telitacicept is designed to selectively inhibit BAFF and APRIL, two cytokines essential for B cell and plasma cell survival, thereby reducing autoreactive B cells and autoantibody production [6] - This dual-target mechanism is believed to restore immune balance in patients, potentially reducing the burden of lupus [2][6] Regulatory Status - Telitacicept is already approved in China for SLE, rheumatoid arthritis, and generalized myasthenia gravis, with ongoing global Phase 3 trials to support potential approval in the United States, Europe, and Japan [7]

Core Viewpoint - RemeGen's telitacicept has shown promising results in treating generalized myasthenia gravis (gMG), with data from a 48-week open-label extension of a Phase III clinical study to be presented at the upcoming AANEM Annual Meeting, indicating its potential as a best-in-class therapy in this field [1][3]. Group 1: Clinical Study Results - The 24-week data from the Phase III study of telitacicept revealed that 98.1% of patients experienced a 3-point improvement in the Myasthenia Gravis Activities of Daily Living (MG-ADL) score, while 87% achieved a 5-point improvement in the Quantitative Myasthenia Gravis (QMG) score [3]. - The complete 48-week data presentation is expected to further emphasize telitacicept's efficacy and safety in treating gMG [3]. Group 2: Licensing and Development - In June 2025, RemeGen out-licensed telitacicept to Vor Bio, which is currently advancing a global multicenter Phase III clinical trial for gMG, with patient recruitment ongoing across multiple regions including the US, Europe, South America, and Asia-Pacific [4]. Group 3: Product Information - Telitacicept is the first-in-class injectable recombinant dual-target fusion protein that inhibits the binding of BLyS and APRIL cytokines to B cell receptors, addressing autoimmune diseases [5]. - The drug has already received approval in China for treating systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and generalized myasthenia gravis (gMG) [5]. Group 4: Market Context - Generalized myasthenia gravis is a rare autoimmune disorder affecting approximately 90,000 patients in the US, 140,000 in Europe, and 29,000 in Japan, highlighting a significant unmet clinical need for effective therapies [7].

Core Insights - Vor Bio's collaborator, RemeGen, achieved the primary endpoint in a Phase 3 clinical study of telitacicept for IgA nephropathy, demonstrating a 55% reduction in proteinuria at 39 weeks compared to placebo [2][3][4] - Telitacicept shows consistent disease-modifying activity across various autoimmune diseases, including myasthenia gravis, Sjögren's disease, and IgA nephropathy, indicating its potential as a best-in-class treatment [3][6] - The study involved 318 adult patients and utilized UPCR as a regulatory marker, reinforcing telitacicept's strong dataset and safety profile [3][4] Company Overview - Vor Bio is a clinical-stage biotechnology company focused on advancing telitacicept, a dual-target fusion protein, through Phase 3 clinical development for autoimmune diseases [5] - RemeGen plans to submit a Biologics License Application (BLA) for telitacicept in IgAN, which would mark its fifth approved indication in China [4][7] Product Details - Telitacicept is designed to treat autoimmune diseases by inhibiting BLyS and APRIL, which are critical for B cell survival, thereby reducing autoreactive B cells and autoantibody production [6][9] - The drug is already approved in China for systemic lupus erythematosus, rheumatoid arthritis, and generalized myasthenia gravis, with ongoing global trials to support further approvals [7][8] Disease Context - IgA nephropathy is a leading cause of chronic kidney disease, with significant unmet needs for effective therapies, as current treatments primarily slow disease progression without addressing underlying causes [8][9] - The overproduction of galactose-deficient IgA1 is identified as a central driver of IgAN, with BAFF and APRIL promoting its production [9]